OR WAIT null SECS
May 14, 2025
In the first part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, shares the key factors that he believes are propelling a continued rise in projected R&D ROI.
Andrew Witty resigns due to personal reasons, as Stephen Hemsley, chairman and former chief executive, will assume the position.
May 12, 2025
The financial decision is due to customer demand stemming from the reshoring of drug supply services.
The President plans to sign an executive order on Monday morning to enforce the trade clause.
April 30, 2025
Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
April 29, 2025
IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.
April 28, 2025
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, describes the uneasiness behind regulatory complications.
The company’s branded form of nadofaragene firadenovec-vncg will also be produced at a hub in Parsippany, NJ.
April 24, 2025
The deal for the San Diego hub provides the CDMO with its first-ever North American manufacturing location for prefilled syringes and cartridges.
April 23, 2025
Joydeep Ganguly, SVP, corporate operations, interim CIO, Gilead Sciences, shares how stakeholders can drive meaningful, lasting impact by turning pledges into proof points, exercising patience, and embedding sustainability into core business operations.